Literature DB >> 24323938

Functional assays for analysis of variants of uncertain significance in BRCA2.

Lucia Guidugli1, Aura Carreira, Sandrine M Caputo, Asa Ehlen, Alvaro Galli, Alvaro N A Monteiro, Susan L Neuhausen, Thomas V O Hansen, Fergus J Couch, Maaike P G Vreeswijk.   

Abstract

Missense variants in the BRCA2 gene are routinely detected during clinical screening for pathogenic mutations in patients with a family history of breast and ovarian cancer. These subtle changes frequently remain of unknown clinical significance because of the lack of genetic information that may help establish a direct correlation with cancer predisposition. Therefore, alternative ways of predicting the pathogenicity of these variants are urgently needed. Since BRCA2 is a protein involved in important cellular mechanisms such as DNA repair, replication, and cell cycle control, functional assays have been developed that exploit these cellular activities to explore the impact of the variants on protein function. In this review, we summarize assays developed and currently utilized for studying missense variants in BRCA2. We specifically depict details of each assay, including variants of uncertain significance analyzed, and describe a validation set of (genetically) proven pathogenic and neutral missense variants to serve as a golden standard for the validation of each assay. Guidelines are proposed to enable implementation of laboratory-based methods to assess the impact of the variant on cancer risk.
© 2013 WILEY PERIODICALS, INC.

Entities:  

Keywords:  BRCA2; VUS; breast cancer; functional analysis; genetic testing; ovarian cancer; variants of uncertain significance

Mesh:

Substances:

Year:  2013        PMID: 24323938      PMCID: PMC3995136          DOI: 10.1002/humu.22478

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  113 in total

1.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

2.  Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells.

Authors:  Cristina Balia; Alvaro Galli; Maria Adelaide Caligo
Journal:  Breast Cancer Res Treat       Date:  2011-06-14       Impact factor: 4.872

Review 3.  Unraveling the mechanism of BRCA2 in homologous recombination.

Authors:  William K Holloman
Journal:  Nat Struct Mol Biol       Date:  2011-07-06       Impact factor: 15.369

4.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Authors:  Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza
Journal:  Lancet Oncol       Date:  2011-08-19       Impact factor: 41.316

5.  A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

Authors:  Kajal Biswas; Ranabir Das; Blanche P Alter; Sergey G Kuznetsov; Stacey Stauffer; Susan L North; Sandra Burkett; Lawrence C Brody; Stefan Meyer; R Andrew Byrd; Shyam K Sharan
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

Review 6.  BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Authors:  Rohini Roy; Jarin Chun; Simon N Powell
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

Review 7.  A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).

Authors:  Noralane M Lindor; Lucia Guidugli; Xianshu Wang; Maxime P Vallée; Alvaro N A Monteiro; Sean Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

8.  ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.

Authors:  Amanda B Spurdle; Sue Healey; Andrew Devereau; Frans B L Hogervorst; Alvaro N A Monteiro; Katherine L Nathanson; Paolo Radice; Dominique Stoppa-Lyonnet; Sean Tavtigian; Barbara Wappenschmidt; Fergus J Couch; David E Goldgar
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

9.  Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.

Authors:  Maxime P Vallée; Tiana C Francy; Megan K Judkins; Davit Babikyan; Fabienne Lesueur; Amanda Gammon; David E Goldgar; Fergus J Couch; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

10.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Authors:  Rinske Drost; Peter Bouwman; Sven Rottenberg; Ute Boon; Eva Schut; Sjoerd Klarenbeek; Christiaan Klijn; Ingrid van der Heijden; Hanneke van der Gulden; Ellen Wientjens; Mark Pieterse; Aurelie Catteau; Pete Green; Ellen Solomon; Joanna R Morris; Jos Jonkers
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

View more
  50 in total

Review 1.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Authors:  D M Eccles; G Mitchell; A N A Monteiro; R Schmutzler; F J Couch; A B Spurdle; E B Gómez-García
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

2.  Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.

Authors:  Lea M Starita; David L Young; Muhtadi Islam; Jacob O Kitzman; Justin Gullingsrud; Ronald J Hause; Douglas M Fowler; Jeffrey D Parvin; Jay Shendure; Stanley Fields
Journal:  Genetics       Date:  2015-03-30       Impact factor: 4.562

3.  Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response.

Authors:  Feng Zhang; Jiazhong Shi; Chunjing Bian; Xiaochun Yu
Journal:  Cell Rep       Date:  2015-10-17       Impact factor: 9.423

4.  Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Lovise Mæhle; Marijke Van Ghelue
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

5.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.

Authors:  Lucia Guidugli; Hermela Shimelis; David L Masica; Vernon S Pankratz; Gary B Lipton; Namit Singh; Chunling Hu; Alvaro N A Monteiro; Noralane M Lindor; David E Goldgar; Rachel Karchin; Edwin S Iversen; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

Review 6.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Authors:  Fergus J Couch; Katherine L Nathanson; Kenneth Offit
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

8.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

9.  ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.

Authors:  Qiang Li; Alexis W Damish; Zoë Frazier; David Liu; Elizaveta Reznichenko; Atanas Kamburov; Andrew Bell; Huiyong Zhao; Emmet J Jordan; S Paul Gao; Jennifer Ma; Philip H Abbosh; Joaquim Bellmunt; Elizabeth R Plimack; Jean-Bernard Lazaro; David B Solit; Dean Bajorin; Jonathan E Rosenberg; Alan D D'Andrea; Nadeem Riaz; Eliezer M Van Allen; Gopa Iyer; Kent W Mouw
Journal:  Clin Cancer Res       Date:  2018-07-06       Impact factor: 12.531

Review 10.  Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.

Authors:  Alvaro N Monteiro; Peter Bouwman; Arne N Kousholt; Diana M Eccles; Gael A Millot; Jean-Yves Masson; Marjanka K Schmidt; Shyam K Sharan; Ralph Scully; Lisa Wiesmüller; Fergus Couch; Maaike P G Vreeswijk
Journal:  J Med Genet       Date:  2020-03-09       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.